StockData
Guided Therapeutics Inc logo

Guided Therapeutics Inc (GTHP) stock

GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.16−0.03 (-15.79%)

Close on Oct 19, 2026Market cap $15.45MP/E –Yield –

Guided Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Guided Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$1.50M. For fiscal 2025 it was -$1.07M. The highest annual figure on record is -$806.00K in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.07M–
FY2024Dec 31, 2024-$1.12M–
FY2023Dec 31, 2023-$1.75M–
FY2022Dec 31, 2022-$1.48M–
FY2021Dec 31, 2021-$1.59M–
FY2020Dec 31, 2020-$1.88M–
FY2019Dec 31, 2019-$806.00K–
FY2018Dec 31, 2018-$1.37M–
FY2017Dec 31, 2017-$1.14M–
FY2016Dec 31, 2016-$1.80M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$319.00K–
Q1 FY2026Mar 31, 2026-$617.00K–
Q4 FY2025Dec 31, 2025-$291.00K–
Q3 FY2025Sep 30, 2025-$277.00K–
Q2 FY2025Jun 30, 2025-$169.00K–
Q1 FY2025Mar 31, 2025-$331.00K–
Q4 FY2024Dec 31, 2024-$332.00K–
Q3 FY2024Sep 30, 2024-$473.00K–
Q2 FY2024Jun 30, 2024-$214.00K–
Q1 FY2024Mar 31, 2024-$100.00K–
Q4 FY2023Dec 31, 2023-$336.00K–
Q3 FY2023Sep 30, 2023-$473.00K–
Q2 FY2023Jun 30, 2023-$438.00K–
Q1 FY2023Mar 31, 2023-$499.00K–
Q4 FY2022Dec 31, 2022-$339.00K-313.2%
Q3 FY2022Sep 30, 2022-$612.00K–
Q2 FY2022Jun 30, 2022-$349.00K–
Q1 FY2022Mar 31, 2022-$179.00K–
Q4 FY2021Dec 31, 2021$159.00K–
Q3 FY2021Sep 30, 2021-$739.00K–
Q2 FY2021Jun 30, 2021-$692.00K–
Q1 FY2021Mar 31, 2021-$320.00K–
Q4 FY2020Dec 31, 2020-$331.00K–
Q3 FY2020Sep 30, 2020-$606.00K–
Q2 FY2020Jun 30, 2020-$408.00K–
Q1 FY2020Mar 31, 2020-$530.00K–
Q4 FY2019Dec 31, 2019-$204.00K–
Q3 FY2019Sep 30, 2019-$228.00K–
Q2 FY2019Jun 30, 2019-$188.00K–
Q1 FY2019Mar 31, 2019-$186.00K–
Q4 FY2018Dec 31, 2018-$311.00K–
Q3 FY2018Sep 30, 2018-$417.00K–
Q2 FY2018Jun 30, 2018-$242.00K-286.2%
Q1 FY2018Mar 31, 2018-$395.00K–
Q4 FY2017Dec 31, 2017-$663.00K–
Q3 FY2017Sep 30, 2017-$204.00K–
Q2 FY2017Jun 30, 2017$130.00K–
Q1 FY2017Mar 31, 2017-$407.00K–
Q4 FY2016Dec 31, 2016-$197.00K–

More Guided Therapeutics figures

See a number that looks wrong?